Newswise — SEATTLE – Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, Wash., and Novo Nordisk, a global health care company headquartered in Denmark, today announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.
The agreement establishes how Novo Nordisk and BRI research scientists and BRI clinicians will collaboratively develop studies to better understand changes in the immune systems of patients living with these autoimmune diseases. The intent is to develop better therapies and improve how these treatments are used.
“Translational research” describes a research approach that seeks to move discoveries made in laboratory, clinical or population studies more quickly into clinical care. In this specific agreement, BRI scientists and Novo Nordisk researchers at the company’s Seattle research center will work together to study samples and data registered in BRI’s biobank of patients with these diseases, as well people with no history of autoimmune disorders. The personal information of these patients will not be disclosed.